微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 77.47% | 122.34% | -7.83% | 22/159 | 50.7% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 84.05% | 171.24% | -10.59% | 14/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 94.01% | 189.53% | 183% | 6/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 33.22% | -2.09% | -4.66% | 108/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 34.84% | 4.04% | 12.43% | 103/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 30.99% | 0.91% | -4.56% | 116/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 32.47% | 4.44% | -4.3% | 107/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 33.93% | 17.01% | 1.31% | 112/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 33.49% | 69.15% | 9.05% | 110/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 30.71% | 128.61% | -1.22% | 115/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 31.09% | 530.82% | 7.22% | 114/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 29% | 55.84% | 46.45% | 123/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 19.8% | 100.73% | 47.39% | 136/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 13.43% | 1461.27% | 286.15% | 140/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | -7.22% | 82.24% | -138.79% | 142/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 18.61% | 161.12% | 88.64% | 142/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 9.86% | 172.85% | 1099.49% | 137/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | -0.99% | 95.63% | 97.57% | 144/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | -40.64% | 26.78% | -33.51% | 134/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | -30.44% | -265.26% | -124.83% | 147/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | -13.54% | -972.26% | 40.08% | 131/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | -22.59% | 69.33% | 59.29% | 139/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | -55.5% | 70.88% | -401.34% | 121/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 18.42% | 136.93% | 1086.71% | 137/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 1.55% | 2% | 102.11% | 116/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | -73.67% | 2% | -47.73% | 127/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | -49.87% | 90.54% | 73.83% | 133/159 | -1232.76% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-03-31 | -190.59% | 2% | 63.86% | 105/159 | 50.75% | 微芯生物 | 95.81% | 行业排名> |
| 2018-12-31 | -527.32% | -656.91% | -656.91% | 131/159 | -210.26% | 微芯生物 | 96.09% | 行业排名> |